X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3867) 3867
Book Review (713) 713
Publication (189) 189
Book / eBook (21) 21
Newsletter (20) 20
Magazine Article (6) 6
Book Chapter (5) 5
Conference Proceeding (4) 4
Dissertation (2) 2
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3622) 3622
index medicus (3517) 3517
female (1938) 1938
male (1848) 1848
middle aged (1618) 1618
oncology (1507) 1507
aged (1392) 1392
pleural neoplasms - drug therapy (1123) 1123
adult (1093) 1093
mesothelioma - drug therapy (1002) 1002
mesothelioma (956) 956
cancer (852) 852
chemotherapy (785) 785
antineoplastic combined chemotherapy protocols - therapeutic use (679) 679
respiratory system (674) 674
mesothelioma - pathology (672) 672
lung neoplasms - drug therapy (666) 666
malignant pleural mesothelioma (648) 648
pleural neoplasms - pathology (628) 628
treatment outcome (619) 619
prognosis (486) 486
antineoplastic agents - therapeutic use (479) 479
lung neoplasms - pathology (478) 478
abridged index medicus (468) 468
animals (458) 458
cisplatin (435) 435
aged, 80 and over (426) 426
surgery (387) 387
cell line, tumor (384) 384
cisplatin - administration & dosage (380) 380
combined modality therapy (363) 363
care and treatment (360) 360
lung cancer (331) 331
pleural effusion (320) 320
tumors (319) 319
pemetrexed (309) 309
mesothelioma - therapy (304) 304
pleural mesothelioma (295) 295
pleural neoplasms - therapy (293) 293
diagnosis (289) 289
neoplasm staging (288) 288
mice (280) 280
retrospective studies (279) 279
mesothelioma - mortality (276) 276
therapy (274) 274
mesothelioma - metabolism (269) 269
pleural neoplasms - surgery (267) 267
research (265) 265
pleural effusion - etiology (264) 264
tomography, x-ray computed (263) 263
survival rate (261) 261
guanine - analogs & derivatives (257) 257
survival (257) 257
pleural neoplasms - mortality (254) 254
expression (252) 252
analysis (243) 243
health aspects (243) 243
pleural effusion, malignant - drug therapy (243) 243
lung-cancer (242) 242
mesothelioma - genetics (242) 242
cell lung-cancer (239) 239
management (231) 231
mesothelioma - surgery (226) 226
apoptosis (225) 225
pleural neoplasms - secondary (223) 223
medicine & public health (217) 217
pleural neoplasms - diagnosis (217) 217
pleural neoplasms - metabolism (209) 209
follow-up studies (207) 207
lung neoplasms - genetics (199) 199
pleural effusions (199) 199
antineoplastic agents - pharmacology (198) 198
mesothelioma - diagnosis (198) 198
survival analysis (196) 196
immunohistochemistry (195) 195
metastasis (190) 190
extrapleural pneumonectomy (189) 189
hematology, oncology and palliative medicine (187) 187
malignant mesothelioma (187) 187
antineoplastic agents - administration & dosage (185) 185
asbestos (185) 185
lung neoplasms - metabolism (179) 179
phase-ii trial (179) 179
pathology (177) 177
pleural effusion, malignant - pathology (176) 176
pleural neoplasms - genetics (176) 176
carcinoma, non-small-cell lung - drug therapy (175) 175
cardiac & cardiovascular systems (172) 172
lung neoplasms - complications (172) 172
lung neoplasms - diagnosis (172) 172
phase-ii (169) 169
pleural effusion - drug therapy (169) 169
pharmacology & pharmacy (168) 168
pleural effusion, malignant - etiology (162) 162
diagnosis, differential (161) 161
immunotherapy (159) 159
lung neoplasms - therapy (159) 159
time factors (153) 153
glutamates - administration & dosage (150) 150
guanine - administration & dosage (150) 150
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (15) 15
Humber River Regional Hospital - Finch Stacks (2) 2
Humber River Regional Hospital - Church Reference (1) 1
Online Resources - Online (1) 1
Providence Healthcare - Reference (1) 1
St Josephs Health Centre - Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Reference (1) 1
West Park Healthcare Centre - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3498) 3498
Japanese (148) 148
French (85) 85
German (76) 76
Italian (23) 23
Spanish (20) 20
Russian (18) 18
Chinese (15) 15
Polish (15) 15
Dutch (3) 3
Hungarian (3) 3
Romanian (3) 3
Danish (2) 2
Norwegian (2) 2
Swedish (2) 2
Turkish (2) 2
Croatian (1) 1
Czech (1) 1
Hebrew (1) 1
Lithuanian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet Oncology, ISSN 1470-2045, 10/2017, Volume 18, Issue 10, pp. 1386 - 1396
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 387, Issue 10026, pp. 1405 - 1414
Journal Article
British Journal of Cancer, ISSN 0007-0920, 01/2010, Volume 102, Issue 1, pp. 220 - 226
BACKGROUND: Radiotherapy for breast cancer reduces disease recurrence and breast cancer mortality. However, it has also been associated with increased second... 
Risk | Breast cancer | Radiotherapy | Second primary neoplasms | Radiation | MORTALITY | QUALITY | LUNG-CARCINOMA | breast cancer | second primary neoplasms | RADIATION-THERAPY | WOMEN | IRRADIATION | CONTRALATERAL BREAST | ONCOLOGY | radiation | INCREASED RISK | radiotherapy | EXPOSURES | risk | SURVIVORS | Esophageal Neoplasms - etiology | Breast Neoplasms - surgery | United States - epidemiology | Soft Tissue Neoplasms - etiology | Follow-Up Studies | Humans | Middle Aged | Breast Neoplasms - etiology | Mastectomy - methods | National Cancer Institute (U.S.) | Bone Neoplasms - epidemiology | Antineoplastic Agents - therapeutic use | Radiotherapy - adverse effects | Esophageal Neoplasms - epidemiology | Lung Neoplasms - etiology | Registries - statistics & numerical data | Antineoplastic Agents, Hormonal - therapeutic use | Adult | Female | Mastectomy - statistics & numerical data | Soft Tissue Neoplasms - epidemiology | Breast Neoplasms - epidemiology | Pleural Neoplasms - epidemiology | Survivors | Combined Modality Therapy | Radiotherapy - statistics & numerical data | Breast Neoplasms - drug therapy | Bone Neoplasms - etiology | Pleural Neoplasms - etiology | Neoplasms, Second Primary - epidemiology | Neoplasms, Second Primary - etiology | Breast Neoplasms - radiotherapy | Lung Neoplasms - epidemiology | Aged | Neoplasms, Radiation-Induced - epidemiology | Index Medicus | Epidemiology
Journal Article
European Journal of Endocrinology, ISSN 0804-4643, 2014, Volume 170, Issue 4, pp. 575 - 582
Journal Article
Cancer, ISSN 0008-543X, 06/2017, Volume 123, Issue 11, pp. 1958 - 1964
Single‐agent nintedanib shows a high rate of disease control with a long duration of disease stabilization in patients with recurrent or metastatic salivary... 
nintedanib | vascular endothelial growth factor receptor (VEGFR) | salivary gland cancer | MANAGEMENT | C-KIT | II TRIAL | SYSTEMIC THERAPY | TUMORS | GROWTH-FACTOR RECEPTOR | ONCOLOGY | ADENOID CYSTIC CARCINOMA | MUTATIONS | INHIBITOR | EXPRESSION | Lung Neoplasms - drug therapy | Humans | Middle Aged | Bone Neoplasms - secondary | Neoplasm Recurrence, Local - drug therapy | Male | Palliative Care | Antineoplastic Agents - therapeutic use | Pleural Neoplasms - drug therapy | Neoplasm Recurrence, Local - pathology | Early Termination of Clinical Trials | Lung Neoplasms - secondary | Treatment Failure | Adult | Carcinoma, Adenoid Cystic - secondary | Female | Bone Neoplasms - drug therapy | Liver Neoplasms - secondary | Republic of Korea | Pleural Neoplasms - secondary | Carcinoma, Adenoid Cystic - drug therapy | Carcinoma, Mucoepidermoid - secondary | Head and Neck Neoplasms - drug therapy | Liver Neoplasms - drug therapy | Carcinoma, Mucoepidermoid - drug therapy | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Head and Neck Neoplasms - pathology | Salivary Gland Neoplasms - drug therapy | Indoles - therapeutic use | Aged | Salivary Gland Neoplasms - pathology | Head and neck cancer | Cancer patients | Care and treatment | Usage | Diagnosis | Fibroblast growth factor receptors | Slopes | Fibroblast growth factor | Adenoid | Minimax technique | Platelet-derived growth factor | Toxicity | Stabilization | Liver | Clinical trials | Metastasis | Anticancer properties | Metastases | Confidence intervals | Elevation | Vomiting | Safety engineering | Protein-tyrosine kinase receptors | Toxic diseases | Neck | Fibroblast growth factor receptor 1 | Vascular endothelial growth factor | Growth factors | Protein-tyrosine kinase | Fibroblast growth factor receptor 2 | Tyrosine | Enzymes | Salivary gland | Nausea | Group dynamics | Patients | Survival | Disease control | Vascular endothelial growth factor receptors | Chemotherapy | Antitumor activity | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 09/2005, Volume 97, Issue 18, pp. 1354 - 1365
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 11/2014, Volume 120, Issue 21, pp. 3311 - 3319
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2006, Volume 12, Issue 19, pp. 5777 - 5785
Purpose: The DNA methylation paradox, manifested as derepression of cancer-testis antigens, and silencing of tumor suppressors during malignant transformation,... 
lung cancer | clinical trial | esophageal cancer | mesothelioma | epigenetics | 5-aza-2′-deoxycytidine | NY-ESO-1 | CELLS | HISTONE DEACETYLASE INHIBITOR | DNA METHYLATION | ONCOLOGY | IMMUNOTHERAPY | 5-AZA-2'-DEOXYCYTIDINE DECITABINE | ANTIGENS | TESTIS GENES | REFRACTORY SOLID TUMORS | PROMOTER | Lung Neoplasms - drug therapy | Genes, p16 - physiology | Pleural Neoplasms - genetics | DNA Modification Methylases - antagonists & inhibitors | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - metabolism | Humans | Lung Neoplasms - metabolism | Middle Aged | Transcriptional Activation | Male | Neoplasm Proteins - metabolism | Pleural Neoplasms - drug therapy | Pleural Neoplasms - metabolism | Esophageal Neoplasms - metabolism | Antigens, Neoplasm - metabolism | Adult | Antimetabolites, Antineoplastic - pharmacology | Female | Membrane Proteins - metabolism | Gene Expression Regulation, Neoplastic - drug effects | Neoplasm Proteins - genetics | Lung Neoplasms - genetics | Antigens, Neoplasm - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Membrane Proteins - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Azacitidine - analogs & derivatives | Mesothelioma - genetics | Mesothelioma - drug therapy | Azacitidine - pharmacology | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Mesothelioma - metabolism | Esophageal Neoplasms - genetics | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Esophageal Neoplasms - drug therapy | Index Medicus
Journal Article
Clinical Lung Cancer, ISSN 1525-7304, 2011, Volume 12, Issue 6, pp. 380 - 386
Micro-Abstract We evaluated EGFR and KRAS mutations between 37 paired primary tumors and corresponding metastases in lung adenocarcinoma. A substantial... 
Hematology, Oncology and Palliative Medicine | Pulmonary/Respiratory | Lung adenocarcinoma | Metastasis | Mutation | Epidermal growth factor receptor | Pleura | GENE-MUTATIONS | PRIMARY TUMORS | GEFITINIB | GROWTH-FACTOR-RECEPTOR | KRAS MUTATION | TREATED PATIENTS | CANCER | LYMPH-NODE METASTASIS | ONCOLOGY | BRAIN METASTASES | PROGRESSION | Adrenal Gland Neoplasms - drug therapy | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | ras Proteins - genetics | Pleural Neoplasms - genetics | Proto-Oncogene Proteins p21(ras) | Adenocarcinoma - pathology | Prognosis | Humans | Middle Aged | Bone Neoplasms - secondary | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Pleural Neoplasms - drug therapy | Brain Neoplasms - secondary | Carcinoma, Non-Small-Cell Lung - secondary | Polymerase Chain Reaction | Aged, 80 and over | Adrenal Gland Neoplasms - secondary | Adult | Female | Adenocarcinoma - genetics | Bone Neoplasms - genetics | Bone Neoplasms - drug therapy | Liver Neoplasms - secondary | Lung Neoplasms - genetics | Pleural Neoplasms - secondary | Liver Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Liver Neoplasms - drug therapy | Brain Neoplasms - genetics | Proto-Oncogene Proteins - genetics | Brain Neoplasms - drug therapy | Mutation - genetics | Adenocarcinoma - drug therapy | Aged | Biomarkers, Tumor - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | DNA, Neoplasm - genetics | Neoplasm Staging | Adrenal Gland Neoplasms - genetics | Index Medicus
Journal Article